Beyond Women's Health: Long-Term Human Papillomavirus-Related Cancer Trends in Norway. [PDF]
Falkenthal TEH, Nygård S, Nygård M.
europepmc +1 more source
Choice and Death: Analysis of Medical Assistance in Dying for Head and Neck Cancer in Ontario
The uptake of MAiD for head and neck cancer (HNC) has been steadily increasing since 2016, when MAiD first became available in Canada. Our study projects a substantial increase in the future use of MAiD for patients with HNC. As such, our health system needs to re‐evaluate and implement the necessary infrastructure to support the projected increase in ...
Tanika Curry +8 more
wiley +1 more source
Transoral Robotic Surgical Resection of Bilateral Parapharyngeal Space Rhabdomyoma. [PDF]
Brady JS +4 more
europepmc +1 more source
Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik +3 more
wiley +1 more source
Improving Prognostic Prediction in Head and Neck Cancer Through a Combined Systemic Immune-Inflammation Index and Prognostic Nutritional Index Score. [PDF]
Miura T +5 more
europepmc +1 more source
Localization and expression of TRPV1 and TRPA1 in the human oropharynx and larynx
D. Álvarez-Berdugo +9 more
semanticscholar +1 more source
The effects of mandatory drug monitoring on opioid use during oropharynx cancer radiotherapy
Saim Mahmood Khan +1 more
openalex +1 more source
ABSTRACT Background Classifying abnormal tongue movements is challenging due to their varied presentations and limited visibility compared to other body parts. Accurate identification of the phenomenology guides physical examination and can point to specific diagnoses.
Nathaniel Bendahan +4 more
wiley +1 more source
Clinical Outcomes of Pembrolizumab in Head and Neck Squamous Cell Carcinoma Subsites Excluded from the KEYNOTE-048 Trial. [PDF]
Yamashita G +19 more
europepmc +1 more source

